CRIS Current Research Information System

PECCI, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.146
NA - Nord America 445
EU - Europa 214
SA - Sud America 55
AF - Africa 20
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.883
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 429
CN - Cina 319
SG - Singapore 304
VN - Vietnam 258
HK - Hong Kong 94
IT - Italia 80
KR - Corea 46
BR - Brasile 43
BD - Bangladesh 32
DE - Germania 30
IN - India 30
NL - Olanda 30
FI - Finlandia 21
JP - Giappone 14
FR - Francia 11
AR - Argentina 9
CA - Canada 9
AT - Austria 8
ID - Indonesia 8
BE - Belgio 6
GB - Regno Unito 6
PH - Filippine 6
RU - Federazione Russa 6
TH - Thailandia 6
CI - Costa d'Avorio 5
IQ - Iraq 5
MX - Messico 5
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
IL - Israele 3
LT - Lituania 3
PL - Polonia 3
SC - Seychelles 3
TW - Taiwan 3
AU - Australia 2
BG - Bulgaria 2
ES - Italia 2
KE - Kenya 2
NI - Nicaragua 2
NP - Nepal 2
SA - Arabia Saudita 2
TR - Turchia 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
GA - Gabon 1
GR - Grecia 1
IE - Irlanda 1
JO - Giordania 1
LY - Libia 1
MA - Marocco 1
ML - Mali 1
MY - Malesia 1
NG - Nigeria 1
SE - Svezia 1
SN - Senegal 1
TJ - Tagikistan 1
TN - Tunisia 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 1.883
Salva come PNG Salva come JPEG
Città #
Singapore 214
Hefei 114
Hong Kong 91
Ashburn 89
Ho Chi Minh City 66
Hanoi 65
San Jose 62
Santa Clara 48
Seoul 43
Boardman 23
Beijing 20
Helsinki 20
Bologna 17
New York 16
Council Bluffs 15
São Paulo 15
Tokyo 13
Bengaluru 11
Buffalo 11
Los Angeles 11
Da Nang 10
Haiphong 10
Shanghai 10
Dallas 9
Falkenstein 9
Nuremberg 9
Frankfurt am Main 8
Hyderabad 8
Lauterbourg 8
San Francisco 8
Can Tho 7
Guangzhou 7
Jakarta 7
Redondo Beach 7
Orem 6
Verona 6
Abidjan 5
Biên Hòa 5
Indianapolis 5
Modena 5
The Dalles 5
Bình Phước 4
Ha Long 4
Hangzhou 4
Rome 4
Tongling 4
Wuhan 4
Amsterdam 3
Brussels 3
Bắc Giang 3
Chengdu 3
Denver 3
Harbin 3
Montreal 3
Mumbai 3
Munich 3
Naples 3
Pietrasanta 3
Quận Một 3
Quận Phú Nhuận 3
Salt Lake City 3
Tel Aviv 3
Tianjin 3
Turin 3
Vienna 3
Warsaw 3
Wuxi 3
Atlanta 2
Baghdad 2
Bonate Sopra 2
Brooklyn 2
Bắc Ninh 2
Catania 2
Foshan 2
Houston 2
Hải Dương 2
Managua 2
Medina 2
Mexico City 2
Milan 2
Moscow 2
Nairobi 2
New Delhi 2
Ninh Bình 2
Pescara 2
Quảng Ngãi 2
Quận Bình Thạnh 2
Salerno 2
Seattle 2
Shenzhen 2
Sofia 2
Sydney 2
Taurianova 2
Thái Bình 2
Thái Nguyên 2
Toronto 2
Vinh 2
Vĩnh Tường 2
Xi'an 2
Yubileyny 2
Totale 1.268
Salva come PNG Salva come JPEG
Nome #
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 216
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 157
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 154
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406] 130
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 121
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 113
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 109
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 104
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 86
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 86
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 84
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 83
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 82
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 80
The gustave roussy immune (Grim)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (nsclc) patients treated with first-line pembrolizumab 78
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 67
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 64
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 60
Non-small-cell lung cancer: how to manage EGFR-mutated disease 58
Totale 1.932
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.893
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20236 0 0 0 0 0 0 0 0 2 2 0 2
2023/202434 0 1 1 2 1 2 2 13 2 4 1 5
2024/2025513 5 42 59 27 74 17 39 24 10 37 56 123
2025/20261.379 234 155 116 114 99 61 134 42 182 107 63 72
Totale 1.932